The application of PET imaging has shown that the response of pancreatic ductal adenocarcinoma after neoadjuvant treatment has changed from morphological assessment to metabolic assessment, especially with the proposal of PET/MRI, playing an important role in predicting treatment outcomes and clinical decision making in these patients. However, due to lack of data, the results need to be further studied.